William W T Aye, Megan R Stark, Kyla-Louise Horne, Leslie Livingston, Sophie Grenfell, Daniel J Myall, Toni L Pitcher, Mustafa M Almuqbel, Ross J Keenan, Wassilios G Meissner, John C Dalrymple-Alford, Tim J Anderson, Campbell Le Heron, Tracy R Melzer
{"title":"早期淀粉样蛋白 PET 再现了帕金森病认知能力下降的代谢特征。","authors":"William W T Aye, Megan R Stark, Kyla-Louise Horne, Leslie Livingston, Sophie Grenfell, Daniel J Myall, Toni L Pitcher, Mustafa M Almuqbel, Ross J Keenan, Wassilios G Meissner, John C Dalrymple-Alford, Tim J Anderson, Campbell Le Heron, Tracy R Melzer","doi":"10.1002/dad2.12601","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Recent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection (\"early phase\") reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid-negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early-phase <sup>18</sup>F-florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD.</p><p><strong>Methods: </strong>One hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual-phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cognitive performance and ASL MRI perfusion.</p><p><strong>Results: </strong>Reduced eFBB uptake was associated with cognitive performance in brain regions previously linked to hypometabolism-associated cognitive decline in PD, independent of amyloid status. Furthermore, eFBB uptake correlated with cerebral perfusion across widespread regions.</p><p><strong>Discussion: </strong>EFBB uptake is a potential surrogate measure for cerebral perfusion/metabolism. A dual-phase PET imaging approach may serve as a clinical tool for assessing cognitive impairment.</p><p><strong>Highlights: </strong>Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism.Parkinson's disease (PD) is a predominantly amyloid-negative condition.Early-phase florbetaben (eFBB) in PD was associated with cognitive performance.eFBB uptake reflects hypometabolism-related cognitive decline in PD.eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion.eFBB distinguished dementia from normal cognition and mild cognitive impairment.Findings were independent of late-phase Aβ burden.Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 2","pages":"e12601"},"PeriodicalIF":4.0000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193095/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.\",\"authors\":\"William W T Aye, Megan R Stark, Kyla-Louise Horne, Leslie Livingston, Sophie Grenfell, Daniel J Myall, Toni L Pitcher, Mustafa M Almuqbel, Ross J Keenan, Wassilios G Meissner, John C Dalrymple-Alford, Tim J Anderson, Campbell Le Heron, Tracy R Melzer\",\"doi\":\"10.1002/dad2.12601\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Recent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection (\\\"early phase\\\") reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid-negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early-phase <sup>18</sup>F-florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD.</p><p><strong>Methods: </strong>One hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual-phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cognitive performance and ASL MRI perfusion.</p><p><strong>Results: </strong>Reduced eFBB uptake was associated with cognitive performance in brain regions previously linked to hypometabolism-associated cognitive decline in PD, independent of amyloid status. Furthermore, eFBB uptake correlated with cerebral perfusion across widespread regions.</p><p><strong>Discussion: </strong>EFBB uptake is a potential surrogate measure for cerebral perfusion/metabolism. A dual-phase PET imaging approach may serve as a clinical tool for assessing cognitive impairment.</p><p><strong>Highlights: </strong>Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism.Parkinson's disease (PD) is a predominantly amyloid-negative condition.Early-phase florbetaben (eFBB) in PD was associated with cognitive performance.eFBB uptake reflects hypometabolism-related cognitive decline in PD.eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion.eFBB distinguished dementia from normal cognition and mild cognitive impairment.Findings were independent of late-phase Aβ burden.Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"16 2\",\"pages\":\"e12601\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193095/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.12601\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.12601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言：最近的研究表明，淀粉样β（Aβ）正电子发射断层扫描（PET）示踪剂在注射后不久（"早期阶段"）的摄取反映了大脑的新陈代谢和灌注。我们在淀粉样蛋白阴性为主的神经退行性疾病--帕金森病（PD）中评估了这种模式，并假设早期18F-氟贝特宾（eFBB）摄取量将再现与帕金森病认知能力下降相关的特征性低代谢和低灌注模式：115名认知功能受损的帕金森病患者接受了双相Aβ PET、结构和动脉自旋标记（ASL）磁共振成像（MRI）以及神经心理学评估。多元线性回归模型比较了 eFBB 摄取与认知能力和 ASL MRI 灌注的关系：eFBB摄取量的降低与认知能力有关，而与淀粉样蛋白状态无关。此外，eFBB摄取与广泛区域的脑灌注相关：讨论：EFBB摄取量是脑灌注/代谢的潜在替代测量指标。双相 PET 成像方法可作为评估认知障碍的临床工具：帕金森病（PD）主要是一种淀粉样阴性疾病。帕金森病患者早期的氟贝特宾（eFBB）与认知能力相关。eFBB与动脉自旋标记磁共振成像测量的脑灌注相关。eFBB可将痴呆症与正常认知和轻度认知障碍区分开来，其结果与晚期Aβ负荷无关。
Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.
Introduction: Recent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection ("early phase") reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid-negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early-phase 18F-florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD.
Methods: One hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual-phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cognitive performance and ASL MRI perfusion.
Results: Reduced eFBB uptake was associated with cognitive performance in brain regions previously linked to hypometabolism-associated cognitive decline in PD, independent of amyloid status. Furthermore, eFBB uptake correlated with cerebral perfusion across widespread regions.
Discussion: EFBB uptake is a potential surrogate measure for cerebral perfusion/metabolism. A dual-phase PET imaging approach may serve as a clinical tool for assessing cognitive impairment.
Highlights: Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism.Parkinson's disease (PD) is a predominantly amyloid-negative condition.Early-phase florbetaben (eFBB) in PD was associated with cognitive performance.eFBB uptake reflects hypometabolism-related cognitive decline in PD.eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion.eFBB distinguished dementia from normal cognition and mild cognitive impairment.Findings were independent of late-phase Aβ burden.Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
